2021
DOI: 10.3390/cancers13030557
|View full text |Cite
|
Sign up to set email alerts
|

Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review

Abstract: Surgery is the mainstay of treatment for localized soft tissue sarcomas (STS). The curative treatment highly depends on complete tumor resection, as positive margins are associated with local recurrence (LR) and prognosis. However, determining the tumor margin during surgery is challenging. Real-time tumor-specific imaging can facilitate complete resection by visualizing tumor tissue during surgery. Unfortunately, STS specific tracers are presently not clinically available. In this review, STS-associated cell … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 10 publications
(12 citation statements)
references
References 172 publications
0
12
0
Order By: Relevance
“…These immunophenotypic characteristics of GISTs provide possible opportunities to develop fluorescent tracers that bind GIST cell-specific biomarkers and improve the feasibility of intraoperative NIRF imaging. Future research should aim to explore the potential of tracers that bind KIT, DOG1, and other biomarkers, described in the literature as helpful for NIRF imaging in malignancies with similar immunophenotypic characteristics to GIST [30].…”
Section: Discussionmentioning
confidence: 99%
“…These immunophenotypic characteristics of GISTs provide possible opportunities to develop fluorescent tracers that bind GIST cell-specific biomarkers and improve the feasibility of intraoperative NIRF imaging. Future research should aim to explore the potential of tracers that bind KIT, DOG1, and other biomarkers, described in the literature as helpful for NIRF imaging in malignancies with similar immunophenotypic characteristics to GIST [30].…”
Section: Discussionmentioning
confidence: 99%
“…A total of eight biomarkers were selected for IHC evaluation based on their potential to detect FGS in MFS. Biomarkers were chosen based on a clinical trial that had already included MFS patients using vascular endothelial growth factor A (VEGF-A) as a target for FGS and a systematic review that selected targets for FGS in soft tissue sarcomas [ 19 , 21 ]. Selected biomarkers were: tumor endothelial marker-1 (TEM-1), vascular endothelial growth factor receptor-1 (VEGFR-1), vascular endothelial growth factor receptor-2 (VEGFR-2), VEGF-A, epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), platelet-derived growth factor receptor-α (PDGFR-α), and cluster of differentiation antigen 40 (CD40, also known as TNFRS5 or p50).…”
Section: Methodsmentioning
confidence: 99%
“…Ideally, this biomarker is still present on residual cells after preoperative therapy. Based on these criteria, promising clinically translatable tumor-specific biomarkers for MFS and other sarcomas have been identified in a recent systematic review [ 21 ]. Since several dedicated NIRF camera systems are already on the market, evaluating a suitable biomarker is currently one of the most important steps to orchestrating successful FGS in MFS [ 22 ].…”
Section: Introductionmentioning
confidence: 99%
“…First, clinically available antibodies and their respective targeting antigens for these tumor types were identified from PubMed and clinicaltrials.gov (Supplementary Tables S1 and S2). This search was restricted to therapeutic antibodies which have been previously or are currently evaluated in clinical trials because these antibodies can be relatively time-and cost-efficiently modified into fluorescent tracers [24,55]. Second, PubMed searches were performed to find important information for target selection (Appendix A).…”
Section: Targeted Fluorescence-guided Surgery For Os Es and Rmsmentioning
confidence: 99%
“…The real-time intraoperative visualization of malignancies could improve resection accuracy by aiding the surgeon discriminate between healthy and malignant tissue. Fluorescence-guided surgery (FGS) is one of the promising technological advances facilitating the visualization of tumors in real-time during surgery [23,24].…”
Section: Introductionmentioning
confidence: 99%